Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy

International Ophthalmology

Volumn 30, Issue 6, 2010, Pages 697-702

  Gulkilik, Gokhan ^a   Taskapili, Muhittin ^b   Kocabora, Selim ^b   Muftuoglu, Gulipek ^c   Demirci, Goktug ^d  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Vakif Gureba Research and Education Hospital   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d Duzce Ataturk Government Hospital   (Turkey)

Author keywords

Bevacizumab; Diabetic retinopathy; Macular edema; Neovascularization

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE INFLAMMATION; EYE TOXICITY; FEMALE; FOLLOW UP; HUMAN; LASER COAGULATION; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA NEOVASCULARIZATION; TREATMENT FAILURE; VISUAL ACUITY; VITREOUS HEMORRHAGE; BIOSYNTHESIS; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; RECURRENT DISEASE; RETINA; RETINA MACULA EDEMA; SPECTACLES;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; EYEGLASSES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; LIGHT COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RETINA; RETINAL NEOVASCULARIZATION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79953045757     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-010-9403-y     Document Type: Article

References (20)

1. Early Treatment Diabetic Retinopathy Study Research Group (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98:823-833
2. Schwartz SG, Flynn HW Jr (2007) Pharmacotherapies for diabetic retinopathy: present and future. Exp Diabetes Res 2007:524-587
3. Diabetes Control Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977-986
4. Vander JF, Duker JS, Benson WE et al (1991) Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 98:1575-1579
5. Fong DS, Aiello LP, Ferris FL III, Klein R (2004) Diabetic retinopathy. Diabetes Care 27:2540-2553 (Pubitemid 39281419)
6. Flynn HW Jr, Chew EY, Simons BD et al (1992) Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. Ophthalmology 99:1351-1357
7. Adamis AP, Miller JW, Bernal MT et al (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450 (Pubitemid 24307211)
8. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487 (Pubitemid 24356306)
9. Adamis AP, Altaweel M, Bressler NM et al (2006) Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113:23-28 (Pubitemid 43021723)
10. Haritoglou C, Kook D, Neubauer A et al (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999-1005 (Pubitemid 44973218)
11. Jorge R, Costa RA, Calucci D (2006) Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26:1006-1013 (Pubitemid 44973219)
12. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
13. Oshima Y, Sakaguchi H, Gomi F (2006) Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142:155-157
14. Avery RL, Pearlman J, Pieramici DJ (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695-1705
15. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275-278 (Pubitemid 44318179)
16. Aiello LP, Brucker AJ, Chang S et al (2004) Evolving guidelines for intravitreous injections. Retina 24:13-19
17. Shimura M, Yasuda K, Nakazawa T et al (2003) Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 110:2386-2394 (Pubitemid 37485170)
18. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H et al (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743-750 (Pubitemid 46483714)
19. Nguyen QD, Tatlipinar S, Shah SM et al (2006) Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142:961-969
20. Diabetic Retinopathy Clinical Research Network (2007) A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114:1860-1867